Better Education on Glomerular Disease: Improving Diagnosis and Treatment of C3 Glomerulopathy

Target Audience
Nephrologists, nephrology physician associates / physician assistants and nurse practitioners, primary care physicians, pediatricians, surgeons who specialize in organ transplants, and other healthcare professionals who may be involved in diagnosis and treatment of patients with C3 glomerulopathy.

Program Overview
Nephrology specialists Carla Nester, MD, and Andrew Bomback, MD, delve into the rare and difficult-to-diagnose disease state of C3 glomerulopathy, a membranoproliferative form of glomerulonephritis. Recent guideline updates and recommended clinical management strategies for the treatment of glomerular disease are reviewed. In addition, the specific pathophysiology, clinical features and diagnosis of C3 glomerulopathy are discussed, as well as the global patient burden of disease and concomitant disease states caused by complement dysregulation. Insight into the historical management of C3 glomerulopathy and targeted therapies currently undergoing evaluation in late clinical trials are provided. Finally, patient resources, supportive measures and clinical perspective on the future of C3 glomerulopathy management are discussed by the faculty.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Discuss recent guideline recommendations on glomerular disease management
Describe the epidemiology and pathophysiology of C3G
Identify the appropriate imaging and testing for diagnosis of C3G
Construct treatment plans for patients diagnosed with C3G
Describe the safety and efficacy of targeted therapies undergoing late-phase clinical trial evaluation in patients with C3G